Clinical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis

Clinical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 253(2023) vom: 25. Aug., Seite 109688
1. Verfasser: Chitnis, Tanuja (VerfasserIn)
Weitere Verfasser: Foley, John, Ionete, Carolina, El Ayoubi, Nabil K, Saxena, Shrishti, Gaitan-Walsh, Patricia, Lokhande, Hrishikesh, Paul, Anu, Saleh, Fermisk, Weiner, Howard, Qureshi, Ferhan, Becich, Michael J, da Costa, Fatima Rubio, Gehman, Victor M, Zhang, Fujun, Keshavan, Anisha, Jalaleddini, Kian, Ghoreyshi, Ati, Khoury, Samia J
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2023
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Clinical validation Gadolinium-positive lesion MS disease activity Multiple sclerosis Blood Proteins Gadolinium AU0V1LM3JT
Beschreibung
Zusammenfassung:Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
An 18-protein multiple sclerosis (MS) disease activity (DA) test was validated based on associations between algorithm scores and clinical/radiographic assessments (N = 614 serum samples; Train [n = 426; algorithm development] and Test [n = 188; evaluation] subsets). The multi-protein model was trained based on presence/absence of gadolinium-positive (Gd+) lesions and was also strongly associated with new/enlarging T2 lesions, and active versus stable disease (composite of radiographic and clinical evidence of DA) with improved performance (p < 0.05) compared to the neurofilament light single protein model. The odds of having ≥1 Gd+ lesions with a moderate/high DA score were 4.49 times that of a low DA score, and the odds of having ≥2 Gd+ lesions with a high DA score were 20.99 times that of a low/moderate DA score. The MSDA Test was clinically validated with improved performance compared to the top-performing single-protein model and can serve as a quantitative tool to enhance the care of MS patients
Beschreibung:Date Completed 26.07.2023
Date Revised 26.07.2023
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2023.109688